Navigation Links
OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer
Date:4/28/2009

PORTLAND, Ore. The Oregon Health & Science University Knight Cancer Institute will evaluate whether the state-of-the-art image-guidance system called Calypso (Calypso Medical, Seattle, Wash.) is as effective in delivering highly precise radiation therapy to head and neck cancer patients as it has been in those with prostate cancer.

"We have been extremely happy with the system's performance for prostate cancer, and it is our hope to apply this system to multiple new body sites in the future. This study represents a real first step in that direction," said Patrick Gagnon, M.D., principal investigator and co-chief resident in the Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine.

The Calypso system relies on three electromagnetic transponders, or beacons, about the size of a grain of rice that are implanted in the prostate prior to beginning treatments. These transponders utilize electromagnetic fields that can be detected with sub-millimeter precision for accurate daily targeting of the prostate gland. Continuous monitoring of the patient and prostate motion is also possible, which allows for greater accuracy in delivering radiation therapy and limits exposure to surrounding healthy tissue.

In this new Phase II clinical trial, the beacons will be implanted into a customized mouth guard fitted to the participant's upper teeth/jaw. With the mouth guard in place, the research team will test whether daily patient positioning can be improved using this system. They will be able to monitor the participant's movement in real time throughout the seven-week course of treatment. This has proved difficult in the past without exposing the patient to additional radiation.

"The Calypso system is unique in allowing the treatment team to continuously monitor the patient's position as the procedure is under way. Unlike other technologies, it doesn't require additional radiation exposure to provide the movement and localization feedback we need," explained Gagnon.

This new research is funded in part through a grant from The American Society of Clinical Oncology (ASCO) Cancer Foundation, which recently awarded Gagnon its highly coveted 2009 Young Investigator Award for his groundbreaking work in this area.

"Only about 30 of these awards are given nationally each year, and only two to four go to radiation oncology junior faculty/trainees. We are proud of Dr. Gagnon's achievement and are excited to be able to offer this leading-edge technology to another group of cancer patients," said Charles Thomas, M.D., chairman of the Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine.

Gagnon will partner with Thomas and John Holland, M.D., associate professor, Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine, in conducting this research.

This work is supported by The ASCO Cancer Foundation Award. Any opinions, findings, conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology or The ASCO Cancer Foundation.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Intrepid USA Healthcare Services Appoints Kathy McKnight as Chief Operations Officer
2. Knights of Columbus to Distribute Wheelchairs to Veterans in Need
3. Knights to Distribute $1 Million Worth of Wheelchairs for Veterans
4. Knights Distribute $1 Million Worth of Wheelchairs to Veterans
5. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
6. Jane M. Knight Recognized By Strathmores Whos Who Worldwide Publication
7. Perr&Knight Announces Discounted Fee Schedule for Access to Its Online Database of Commercial Lines Competitor Filings
8. UF McKnight Brain Institute director honored by Italian scientists
9. Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firms Public Policy & Regulation Practice
10. Knights of Columbus Ultrasound Program Assists Pregnant Women
11. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery community, ... forum section was recently revamped and upgraded to allow even more interaction between doctors ... the country. , According to the senior editor of Cosmetic Town, “We are excited ...
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon ... collaborating with doctors and hospitals to make transformative changes in how health care ... therapy minds this week in discussing breakthroughs in cellular medicine to treat disease. ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... PA (PRWEB) , ... April 28, 2016 , ... ... Browne, M.D. has been named a Top Doc in Physical Medicine and Rehabilitation ... conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership ...
(Date:4/28/2016)... ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her ... again much like a tsunami and took on a more spiritual tone. The desire to ... to do more with it than just file it away. Friends would ask her how ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology: